Entering text into the input field will update the search result below

Vaxart's oral flu vaccine shows positive action in challenge study; shares ahead 38% premarket.

Oct. 04, 2018 9:16 AM ETVaxart, Inc. (VXRT) StockBy: Douglas W. House, SA News Editor6 Comments
  • Ultra-thinly traded nano cap Vaxart (NASDAQ:VXRT) is up 38% premarket on increased volume, albeit on only 16K shares, on the heels of its announcement of positive data from a Phase 2 challenge study of its H1 influenza oral tablet vaccine. The results will be presented this Saturday, October 6, at IDWeek in San Francisco.
  • The vaccine elicited a significant expansion of mucosal homing receptor α4β7+ (β7+) plasmablasts, cells that play a key role in an immune response, to about 60% of all activated B cells, significantly higher than 20% from Sanofi's (SNY) Fluzone.
  • It also generated protective hemagglutinin inhibition (HAI) antibodies in serum, similar to conventional injectable flu vaccines.
  • As previously reported, 37% of participants receiving the Vaxart vaccine developed influenza infection after challenge compared to 44% for Fluzone and 71% for placebo.
  • Development is ongoing.

Recommended For You

About VXRT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
VXRT--
Vaxart, Inc.